Tibet Weixinkang Medicine(SH:603676)2024-03-01 07:37Group 1: Company Overview - The company is Tibet Weixin Kang Pharmaceutical Co., Ltd., with stock code 603676 [2] - The meeting was held in Beijing and Shanghai, with the board secretary Yu Haibo presenting the company's basic situation [3] Group 2: Market Impact and Sales Projections - The impact of the Henan 19 Province Alliance procurement on the sales of injectable multivitamins (12) is significant, with 9 provinces already executing the selected results and 10 more expected to follow in the coming months [3] - The sales revenue for injectable multivitamins (12) is anticipated to increase due to exclusive selection in public medical institutions, despite a decrease in procurement prices compared to the original benchmark [3] - The sales revenue for multiple trace element injection reached 86.93 million yuan in the first half of 2023, representing a year-on-year growth of 3.68% [3] Group 3: Competitive Landscape - Currently, only Weixin Kang and Baxter have obtained registration for injectable multivitamins (12) [3] - The compound electrolyte injection (V) is a domestic first imitation product, with 2 companies approved, including Weixin Kang [4] Group 4: Product Development and Market Strategy - As of March 1, 2023, the pediatric multivitamin injection (13) has covered over 300 hospitals, laying a solid foundation for sales growth [4] - The company is actively adjusting sales strategies in response to regional procurement conditions and is focusing on new product development in the trace element field [3][4]